Marksans Pharma logo

Marksans Pharma financials and balance sheet

NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap

Formerly Tasc Pharmaceuticals
Last close ₹286.90down ₹7.55 (2.56%)BSE ₹286.75

Share price at the NSE close on 23 Oct 2026. Previous close ₹294.45.

52-week range of traded prices to 23 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
Market cap
₹13,001 Cr592nd largest listed
P/E
25.2
P/B
4.3
Dividend yield
0.31%
ROE
17.1%
ROCE
19.9%
Debt to equity
0.01
Volume, NSE
14,14,61953.0% delivered

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Marksans Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 3.6% of operating profit in the first full year.

The years either side of a change of basis do not compare. From the year to Mar 2020, the company's revenue for that year, ₹433 Cr, differs from its quarters added, ₹424 Cr.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue1,341
  2. Materials and goods−679
  3. Employee costs−122
  4. Other expenses−217
  5. Operating profit324
  6. Depreciation−34
  7. Other income+104
  8. One-off items0.0
  9. Finance costs−1.3
  10. Profit before tax392
  11. Tax−91
  12. Net profit301

What the company owns

  • Plant, investments and other assets₹735 Cr
  • Receivables₹623 Cr
  • Cash and bank₹447 Cr
  • Inventory₹189 Cr

What pays for it: net worth and liabilities

  • Net worth₹1,652 Cr
  • Owed to suppliers₹181 Cr
  • Other liabilities₹161 Cr

Profit and loss

Standalone, ₹ crore, years to March.Marksans Pharma quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 6 JunMar 2020Filed 2 JunMar 2021Filed 1 JunMar 2022Filed 31 MayMar 2023Filed 31 MayMar 2024Filed 1 JunMar 2025Filed 12 JunMar 2026Filed 26 May
Revenue from operations2162954244336006586558531,1741,341
1922583613624865455637139701,018
Materials and goods bought112169236243338378394479640679
Employee costs4046464955605677102122
Other expenses3943787093107113157229217
Operating profit before depreciation2436637111411492140204324
Operating margin11.2%12.4%14.9%16.5%19.0%17.3%14.0%16.4%17.4%24.1%
Materials, % of revenue52.1%57.5%55.7%56.1%56.4%57.4%60.2%56.1%54.5%50.6%
Employee costs, % of revenue18.6%15.6%10.9%11.2%9.1%9.2%8.6%9.0%8.7%9.1%
Other expenses, % of revenue18.1%14.6%18.4%16.2%15.6%16.2%17.2%18.4%19.5%16.2%
Depreciation and amortisation1512912151817292934
Operating profit after depreciation9245560999675111175289
Other income70803142606270104
Finance costs3877544111
One-off items––00000000
Profit before tax13175653124135132172243392
041215263129385591
Net profit1212443898104103134188301
Other comprehensive income––0000−1001
Total comprehensive income––443898104102134188302
Net margin5.7%4.2%10.3%8.7%16.4%15.8%15.7%15.7%16.0%22.4%
Earlier years, Mar 2008 to Mar 2016
₹ croreMar 2008Mar 2009Mar 2010Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016
Revenue from operations243211201157157196318409367
207183176169–148231290254
Materials and goods bought––134–88103170218178
Employee costs–––––15212426
Other expenses–––––30404850
Operating profit before depreciation362725−12–4887119113
Operating margin14.9%13.0%12.5%−7.8%–24.7%27.4%29.1%30.7%
Materials, % of revenue–––––52.3%53.3%53.4%48.6%
Employee costs, % of revenue–––––7.8%6.7%5.8%7.1%
Other expenses, % of revenue–––––15.2%12.6%11.8%13.6%
Depreciation and amortisation9101015–99915
Operating profit after depreciation281815−27–407811098
Other income6––––––––
Finance costs141515106121015136
Profit before tax2021−133−18330639792
Tax3205−2−1083020
Net profit1710−218−18140566771
Net margin7.2%0.2%0.1%−138.6%−115.7%20.1%17.5%16.4%19.5%
Standalone, ₹ crore, years to March.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Filed 6 JunMar 2020Filed 2 JunMar 2021Filed 1 JunMar 2022Filed 31 MayMar 2023Filed 31 MayMar 2024Filed 1 JunMar 2025Filed 12 JunMar 2026Filed 26 May
4715066007851,1111,2231,3831,652
Share capital4141414145454545
Reserves4304655597441,0661,1771,3381,607
Borrowings770050000
1236095167217272346310
1828241417212631
Total assets6125947199661,3451,5161,7551,994
340353369376431568673685
2722413495909149481,0821,309
Net debt76−3−106−219−441−339−269−447
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Filed 1 JunMar 2022Filed 31 MayMar 2023Filed 31 MayMar 2024Filed 1 JunMar 2025Filed 12 JunMar 2026Filed 26 May
10751523431211
12783837378284
12−44−60−83−158−83
Receivables15−71−60−70−183−63
Inventories−19−10−27−60−1416
Payables811384844−23
Other working capital926−100−5−12
Tax paid−20−32−32−39−47−73
Capital spending21233515612049
Free cash flow862816−122−89162
9−8−195−11417−140
−1476210−26−30−39
Dividends paid41110232736
Shares bought back0040000
Shares issued00275000
Net change in cash10211867−1061832
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.Marksans Pharma dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 6 JunMar 2020Filed 2 JunMar 2021Filed 1 JunMar 2022Filed 31 MayMar 2023Filed 31 MayMar 2024Filed 1 JunMar 2025Filed 12 JunMar 2026Filed 26 May
Earnings per share₹0.30₹0.30₹1.07₹0.93₹2.40₹2.54₹2.48₹2.95₹4.15₹6.64
Diluted earnings per share₹0.30₹0.30₹1.07₹0.93₹2.40₹2.54₹2.48₹2.95₹4.15₹6.63
Dividend per share₹0.05₹0.05₹0.05₹0.10₹0.25₹0.25₹0.50₹0.60₹0.80₹0.90
Book value per share––₹11.50₹12.35₹14.65₹19.17₹24.52₹26.98₹30.53₹36.46
Dividend payout16.7%16.5%4.7%10.8%10.4%9.8%22.0%20.3%19.3%13.6%
Shareholder yield––––0.2%0.6%−7.0%0.3%0.3%0.5%
Market cap at the year end (₹ crore)1,9301,2951,0215692,0451,8623,1906,88410,0827,110

Ratios

Standalone, years to March.Marksans Pharma PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 6 JunMar 2020Filed 2 JunMar 2021Filed 1 JunMar 2022Filed 31 MayMar 2023Filed 31 MayMar 2024Filed 1 JunMar 2025Filed 12 JunMar 2026Filed 26 May
Revenue growth–36.5%43.9%–38.3%9.8%−0.5%30.2%37.6%14.2%
Operating profit growth–50.7%73.7%–59.1%0.0%−19.2%52.3%45.8%58.6%
Net profit growth−82.9%1.6%251.0%−13.1%159.6%5.7%−1.1%30.0%40.8%59.7%
Earnings per share growth–0.0%256.7%−13.1%158.1%5.8%−2.4%19.0%40.7%60.0%
––9.3%7.8%17.8%15.0%10.9%11.5%14.4%19.8%
–––−1.5 pts10.0 pts−2.8 pts−4.2 pts0.6 pts3.0 pts5.4 pts
From the net margin–––−1.4 pts6.8 pts−0.7 pts−0.1 pts0.0 pts0.3 pts5.8 pts
From asset turnover–––0.3 pts3.9 pts−2.5 pts−4.1 pts0.6 pts2.4 pts−0.1 pts
From borrowing–––−0.4 pts−0.7 pts0.4 pts0.0 pts0.1 pts0.3 pts−0.3 pts
Return on capital employed––10.0%11.8%16.4%12.2%6.8%9.1%12.6%17.5%
Cash conversion––––108.8%49.0%50.3%25.5%16.5%70.2%
Interest cover2.73.28.38.218.425.320.8112.2148.7218.0
Debt to equity––0.160.000.000.010.000.000.000.00
Receivable days––15313689137170158171170
Inventory days––109112101100121145117102
Payable days––5776697210312211697
Cash conversion cycle, days––204172121165188182172174
Working capital days––19314990113143144145150
Asset turnover––0.690.720.910.780.570.600.720.72
Assets per rupee of net worth––1.301.241.191.221.221.231.261.24
Sales per rupee of plant––4.364.325.414.994.653.183.323.64
Capital spending to depreciation––––1.381.292.115.344.071.43
Plant being built, % of plant in use––––––2.8%0.0%––
Revenue growth and operating profit growth are left blank for the years to Mar 2017 and Mar 2020: between the two periods the company restated its earlier figures, so the two are on different bases and the change is not worked out. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
16.0%
Cash from operations against operating profit
65.2%
Measure10 years5 years3 years
Revenue growth, yearly rate13.8%17.5%27.0%
Profit growth, yearly rate15.4%25.0%43.0%
Return on equity, average–14.3%15.2%
Return on capital employed, average–11.6%13.1%
Operating margin, average16.3%17.8%19.3%
Net margin, average13.1%17.1%18.0%
Asset turnover, average–0.680.68
Cash conversion cycle, days, average–176176
Interest cover, average56.6105.0159.6
Debt to equity, average–0.000.00

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations379276211
Cash from investing−440−237−140
Cash from financing191−95−39
Capital spending38232449
Dividends paid1078636
Shares bought back4000
Shares issued for cash27500
Borrowings raised500
Borrowings repaid500

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 966
Altman Z-scorePublished threshold 1.8118.97–
Beneish M-scorePublished threshold −1.78−1.53−2.19
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets8.5612.26
Cash from operations to profit, 3 yearsPublished threshold 0.7 times0.270.44
Receivables growth less revenue growthOur threshold 0 percentage points10.83−0.79
Inventory growth less cost-of-goods growthOur threshold 0 percentage points−26.09−13.91
Other current assets growth less revenue growthOur threshold 5 per cent of revenue0.90−0.62
Effective tax ratePublished threshold 17.16 per cent22.60–
Tax charged less tax paid, % of profitOur threshold 10 percentage points3.47–
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
7 Oct 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Proposed fund based limitsLong-term scaleCARE AA-Review, Re-affirmStable35
7 Oct 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-Proposed non fund based limitsShort-term scaleCARE A1+Review, Re-affirm25
7 Oct 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-Forward ContractShort-term scaleCARE A1+Review, Re-affirm18.75
7 Oct 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-Bank GuaranteeShort-term scaleCARE A1+Review, Re-affirm2
7 Oct 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-Letter of creditShort-term scaleCARE A1+Review, Re-affirm75
7 Oct 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Cash CreditLong-term scaleCARE AA-Review, Re-affirmStable100
4 Jun 2026India Ratings and Research Private Limited (opens in a new tab)Bank loan facilitiesIND AA-; IND A1+Review, OtherPositive195.75
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.